IOVAIOVANCE BIOTHERAPEUTICS, INC.

Nasdaq iovance.com


$ 10.96 $ -2.48 (-18.48 %)    

Friday, 10-May-2024 15:59:56 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 10.965
$ 13.40
$ 0.00 x 0
$ 0.00 x 0
$ 10.70 - $ 13.40
$ 3.21 - $ 18.33
19,119,878
na
2.92B
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-04-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 03-09-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-08-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 iovance-biotherapeutics-q1-2024-gaap-eps-042-inline-sales-715000k-miss-2075m-estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.42) per share which met the analyst consensus estimate. ...

 ahn-cancer-institute-to-offer-groundbreaking-treatment-for-metastatic-melanoma-the-one-time-treatment-made-by-iovance-biotherapeutics-is-the-first-fda-approved-t-cell-therapy-for-solid-tumors

Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a firs...

 piper-sandler-maintains-overweight-on-iovance-biotherapeutics-raises-price-target-to-19

Piper Sandler analyst Joseph Catanzaro maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the pric...

 truist-securities-maintains-buy-on-iovance-biotherapeutics-raises-price-target-to-26

Truist Securities analyst Asthika Goonewardene maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the pri...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 wells-fargo-maintains-overweight-on-iovance-biotherapeutics-raises-price-target-to-25

Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target ...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION